Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461591 · ClinicalTrials.gov registry record · Phase 3
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 802
- Enrollment target
NCT00461591 is a Phase 3 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 802 participants.
The verdict
NCT00461591, a Phase 3 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 802 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
Interventions
- DRUG Placebo
- PROCEDURE TURBT
- DRUG Apaziquone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 802 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461591
The ClinicalTrials.gov registry entry for NCT00461591 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 802 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00461591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461591 about?
NCT00461591 is a clinical study titled "Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)". The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
What is the current status of trial NCT00461591?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 802 participants. The study started on 2007-04. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00461591?
The interventions under investigation include: Placebo (DRUG), TURBT (PROCEDURE), Apaziquone (DRUG).
Who is sponsoring clinical trial NCT00461591?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.